The government discarded COVID-19 oral medicines believed to be worth around 240 billion yen ($1.6 billion) in the fiscal ...

The Japanese government discarded Covid-19 oral medicines believed to be worth around 240 billion yen (RM6.85 billion) in the ...

The Japanese government discarded Covid-19 oral medicines believed to be worth around 240 billion yen (US$1.6 billion) in the ...

No improvement in clinical outcomes occurred among inpatients with COVID-19 who received nirtmatrelvir-ritonavir or molnupiravir in addition to usual care.

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

The addition of molnupiravir or nirmatrelvir-ritonavir to usual care does not reduce 28-day mortality or improve other clinical outcomes in patients hospitalized with COVID-19.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

On July 9, Merck announced that it would acquire Verona Pharma, a U.K.-based biotechnology company specializing in the development of medicines for respiratory diseases. Merck will pay $10 billion in ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal. The deal gives Merck access to Verona Pharma's new chronic ...

Merck (known as MSD outside of the US and Canada) has announced plans to acquire London-based Verona Pharma for approximately $10 billion, aiming to bolster its respiratory treatment offerings. The ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal ...